New Clinical Data Shows Pirepemat Reduces Falls

At the AD/PD™ 2026 conference in Copenhagen, IRLAB Therapeutics presented significant Phase IIb clinical trial results for its lead candidate, pirepemat. The study indicates that this novel medication could offer a much-needed solution for one of the most challenging aspects of the condition: impaired balance and the resulting frequency of falls. Targeting the "Balance Center" of the Brain While current treatments are highly effective at managing tremors and stiffness by focusing on dopamine, they often fail to address "axial" symptoms like postural instability. These balance issues are primarily linked to a different neurotransmitter called acetylcholine in the frontal cortex. Pirepemat is a first-in-class cortical enhancer designed to strengthen this cholinergic signalling. By improving the brain's ability to process sensory information and coordinate complex movements, the drug aims to restore stability and prevent the "freezing" or stumbling that leads to injuries. Key Findings from the Phase IIb Study The REACT study was a double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of pirepemat over 12 weeks. The data revealed several promising outcomes: Significant Reduction in Falls: Participants receiving the optimal dose of pirepemat experienced a clinically meaningful reduction in the frequency of falls compared to the placebo group. Improved Cognitive Control: Because the drug targets the frontal cortex, researchers noted improvements in "executive function"—the mental process that allows a person to navigate obstacles and adjust their balance in real-time. Safety and Tolerability: The medication was well-tolerated, with no significant increase in the side effects typically associated with traditional balance medications, such as excessive sleepiness or confusion. Why This Matters for the Community Falls are a leading cause of hospitalisation and a significant factor in the loss of independence for people with the condition. Unlike existing therapies that sometimes worsen balance as a side effect, pirepemat offers a targeted way to reinforce the brain's natural stability mechanisms. The success of this Phase IIb trial paves the way for a larger Phase III study. If these results are replicated, pirepemat could become the first approved therapy specifically indicated for the prevention of falls. This would represent a major shift in care, moving beyond simply managing movement to actively protecting the physical safety and autonomy of those living with the condition.